


## SUCCESSFULLY TRANSITIONING GENE-THERAPY PRODUCTS FROM LAB TO INDUSTRIAL ENVIRONMENT



An essential part is the transition from the lab-table environment to the industrial environment. This transition is based on:

- Defining a process & product
- Embed robustness into process and product quality
- Meeting external expectations (authorities)
- Multidisciplinary cooperation

## LARGE DIVERSITY GENE TECHNOLOGY AREA



Technology area	Technology
Gene Delivery	<ul style="list-style-type: none"> <li>• Viral vectors</li> <li>• Non-viral vectors (lipids/liposomes; polymers, nanoparticles) plasmid DNA</li> </ul>
Gene Expression regulation	<ul style="list-style-type: none"> <li>• siRNA and miRNA</li> <li>• Antisense Oligonucleotides</li> </ul>
Genome / epigenome editing	<ul style="list-style-type: none"> <li>• Engineered nuclease (CRISPR/Cas 9, TALENS, ZNF)</li> </ul>

### Examples of approved gene therapy products:

Glybera, AAV (LPLD)  
Approved 2012


Imlygic, Herpes simplex (Melanoma)  
Approved 2015

Strimvelis, ex-vivo retroviral vector (Immunodeficiency)  
Approved 2016

Zalmonis, ex-vivo retroviral vector (Cancer, stem cell transplantation)  
Approved 2016



## BASIC PRODUCT DEVELOPMENT



## CMC PROCESS DEVELOPMENT

Process and product quality used for POC (Q)TPP- Dosage, patient population, administration, etc.

Identify required process scale

Define process steps


Specify analytics and process control

Optimize process steps and generate batches

Reducing variation and building process robustness

Process Lock

**ANALYTICS**



**PROCESS**

## CMC ANALYTICS

Gene therapy products are complex. An analytical package should be capable to:

- demonstrate consistency (lot to lot)
- assess the suitability of the product for its intended use.

Basic testing program (ICH Q6B):

Biological activity (potency, infectivity)

Identify (DNA, protein)

Impurities (process&product related)

Content (GC, protein&DNA composition, total particles, total protein)

Contaminants (endotoxin, sterility)

Purity (ratio tp/gc)

Physicochemical (pH, osm, extract. vol.)

## CMC FOCUS THROUGHOUT DEVELOPMENT

- To develop a gene-therapy product, an integrated CMC focus is required.
- Integration of multidisciplinary teams and agreement on the target product profile is essential for successful development of a gene-therapy product.
- Changing a process&product from limited specified to defined requires an iterative approach.
- Knowledge drives this iterative approach.
- External expectations are outlined in guidelines.
- Understanding internal and external expectations should be part of an integrated CMC focus.